[EHA Special Lecture] Recent therapeutic algorithms in multiple myeloma
Pieter Sonneveld is Professor of Hematology at the Department of Hematology and Head of the Erasmus MC Cancer Institute at the Erasmus MC and the Erasmus University in Rotterdam, the Netherlands. He received his medical degree from the Erasmus University Rotterdam and completed his PhD at the University of Leiden, The Netherlands. He received a Fogarty fellowship and worked at the National Cancer Institute in the United States before completing his hematology training.
Professor Sonneveld is chairman of the Dutch HOVON Myeloma Group and performed many clinical trials. He was one of the founders of the European Myeloma Network (EMN) and currently the chairman of the Board. Within EMN, he organized a cooperative network for large clinical trials, which has resulted in four large European Intergroup trials and scientific workshops for the standardization of diagnostic methods in Europe.
He has performed several functions in the European Hematology Association (EHA), including scientific chairman of the annual meeting. Professor Sonneveld was elected President of EHA in June 2017. He is chair of the Scientific Working Group Committee which coordinates research. Also he has founded the Clinical Research Training Program CRTH and the new journal Hemasphere.
He serves on the scientific advisory boards of the International Myeloma Foundation (IMF), the International Myeloma Working Group, the International Myeloma Society and and other collaborative efforts. He has been a member of the Editorial Boards of Blood, Leukemia, Leukemia Research, Haematologica, European Journal of Cancer and Annals of Haematology. Professor Sonneveld is the author of more than 450 scientific publications in peer reviewed journals and several book chapters. He holds several patents on genetic profiling of myeloma. In 2015 Professor Sonneveld received the Robert F. Kyle Lifetime Achievement Award for his work on Multiple Myeloma.
Professor Sonneveld is chairman of the Dutch HOVON Myeloma Group and performed many clinical trials. He was one of the founders of the European Myeloma Network (EMN) and currently the chairman of the Board. Within EMN, he organized a cooperative network for large clinical trials, which has resulted in four large European Intergroup trials and scientific workshops for the standardization of diagnostic methods in Europe.
He has performed several functions in the European Hematology Association (EHA), including scientific chairman of the annual meeting. Professor Sonneveld was elected President of EHA in June 2017. He is chair of the Scientific Working Group Committee which coordinates research. Also he has founded the Clinical Research Training Program CRTH and the new journal Hemasphere.
He serves on the scientific advisory boards of the International Myeloma Foundation (IMF), the International Myeloma Working Group, the International Myeloma Society and and other collaborative efforts. He has been a member of the Editorial Boards of Blood, Leukemia, Leukemia Research, Haematologica, European Journal of Cancer and Annals of Haematology. Professor Sonneveld is the author of more than 450 scientific publications in peer reviewed journals and several book chapters. He holds several patents on genetic profiling of myeloma. In 2015 Professor Sonneveld received the Robert F. Kyle Lifetime Achievement Award for his work on Multiple Myeloma.
Abstract password authentication.
Password is written on a program and abstract book.